Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Colleen S SteinDepartment of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.ORCID 0000-0002-7676-6278
Connor R LinzerDepartment of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.ORCID 0009-0009-9838-5845
Collin D HeerFree Radical and Radiation Biology Program, Department of Radiation Oncology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA.
Nathan H WitmerDepartment of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
Jesse D CochranDepartment of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.ORCID 0000-0001-9705-5785
Douglas R SpitzFree Radical and Radiation Biology Program, Department of Radiation Oncology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA.
Ryan L BoudreauDepartment of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.ORCID 0000-0002-9800-5349
Funding
Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Jong Sung Kim · 1990 to 2026
$40.5M
TRAINING PROGRAM IN FREE RADICAL AND RADIATION BIOLOGYT32CA078586 · NCI · UNIVERSITY OF IOWA · PI SPITZ, DOUGLAS ROBERT · 1999 to 2024
$5.7M
Predoctoral Training in the Pharmacological SciencesT32GM067795 · NIGMS · UNIVERSITY OF IOWA · PI STRACK, STEFAN · 2004 to 2021
$3.4M
Genetic and Molecular Mechanisms of Heart DiseaseR35HL177241 · NHLBI · UNIVERSITY OF IOWA · PI RYAN L BOUDREAU · 2025 to 2026
$2.1M
The physiologic and genomic relevance of mitoregulin in ischemic heart failureR01HL150557 · NHLBI · UNIVERSITY OF IOWA · PI BOUDREAU, RYAN L · 2020 to 2023
$1.5M
The genomic interface of microRNA regulation and heart failureR01HL148796 · NHLBI · UNIVERSITY OF IOWA · PI BOUDREAU, RYAN L · 2019 to 2022
$1.5M
Elucidating and exploiting NAD metabolic defects in cancerK00CA245722 · NCI · YALE UNIVERSITY · PI HEER, COLLIN DAVID · 2021 to 2024
$378k
Selective targeting of tumor cell redox metabolism and DNA damage responses to enhance cancer therapyF99CA245722 · NCI · UNIVERSITY OF IOWA · PI HEER, COLLIN DAVID · 2019 to 2020
Mitoregulin (MTLN) is a 56-amino-acid mitochondrial microprotein known to modulate mitochondrial energetics. MTLN gene expression is elevated broadly across most cancers and has been proposed as a prognostic biomarker for non-small cell lung cancer (NSCLC). In addition, lower MTLN expression in lung adenocarcinoma (LUAD) correlates with significantly improved patient survival. In our studies, we have found that MTLN silencing in A549 NSCLC cells slowed proliferation and, in accordance with this, we observed the following: (1) increased proportion of cells in the G1 phase of cell cycle; (2) protein changes consistent with G1 arrest (e.g., reduced levels and/or reduced phosphorylation of ERK, MYC, CDK2, and RB, and elevated p27
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Mitoregulin Promotes Cell Cycle Progression in Non-Small Cell Lung Cancer Cells. · full record | Socratic